Genetic Associations with Therapy Response in the HOVON-65/GMMG-HD4 Trial in Patients with Multiple Myeloma
Multiple Myeloma (MM) is a plasma cell malignancy, characterized by
significant heterogeneous disease progression and response to therapy. It is very likely that genetic polymorphisms of genes involved in drug absorption, distribution, metabolism and excretion may affect a patient’s response to
Click on the PDF tab to view and download the document.